Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Reexamination Certificate
2008-03-11
2008-03-11
Salimi, Ali R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
C424S211100, C435S069100
Reexamination Certificate
active
07341729
ABSTRACT:
The present invention relates to recombinant bovine para influenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.
REFERENCES:
patent: 5869036 (1999-02-01), Belshe et al.
patent: 6764685 (2004-07-01), Haller et al.
patent: 6811784 (2004-11-01), Haller et al.
patent: WO 89/10405 (1989-11-01), None
patent: WO 93/14207 (1993-07-01), None
patent: WO 97/34008 (1997-09-01), None
patent: WO 98/53078 (1998-11-01), None
patent: WO 01/04320 (2001-01-01), None
Breker-Klassen et al., 1996, “Comparisons of the F and HN gene sequences of different strains of bovine parainfluenza virus type 3: relationship to phenotype and pathogenicity,” Can. J. Vet. Res. 60:228-236.
Dimock and Collins, 1993, “Rescue of synthetic analogs of genomic RNA and replicative-intermediate RNA of human parainfluenza virus type 3,” J. Virol. 67:2772-2778.
Durbin et al., 1997, “Recovery of infectious parainfluenza virus type 3 from cDNA,” Virol. 235:323-332.
Haller, et al., (2000) “Expression of the Surface Glycoproteins of Human Parainfluenza Virus Type 3 by Bovine Parainfluenza Virus Type 3, a Novel Attenuated Virus Vaccine Vector,”J. Virology 74(24):11626-11635.
Karron et al., 1996, “Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants,” Pediatr. Infect. Dis. J. 15:650-654.
Karron et al., 1995, “A Live Attenuated Bovine Parainfluenza Virus Type 3 Vaccine is Safe, Infectious, Immunogenic, and Phenotypically Stable in Infants and Children,” J. of Infect. Diseases 171:1107-1114.
Klippmark et al., 1990, “Antigenic variation of human and bovine parainfluenza virus type 3 strains,” J. Gen. Virol. 71:1577-1580.
Palese et al., 1996, “Negative-strand RNA viruses: genetic engineering and applications,” Proc. Natl. Acad. Sci. USA 93:11354-11358.
Schmidt et al., 2000, “Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates,”J. Virol. 74(19):8922-8929.
Shibuta et al., 1979, “Characterization of bovine parainfluenza virus type 3”, Microbiol. Immunol. 23:617-628.
Skiadopoulos et al., 2001, “A chimeric human-bovine parainfluenza virus type 3 expressing measles virus hemagglutinin is attenuated for replication but is still immunogenic in rhesus monkeys,” J. Virol. 75(21):10498-10504.
Skiadopoulos et al., 1998, “Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attentuated vaccine candidate cnontribute to its temperature-sensitive and attenuation phenotypes,” J. Virol. 72(3):1762-1768.
Tao et al., 1999, “A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge,” Vaccine 17:1100-1108.
Tao et al., 1998, “Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1,” J. Virol. 72:2955-2961.
Coelingh Kathleen L.
Haller Aurelia
MedImmune Vaccines, Inc.
Salimi Ali R.
LandOfFree
Recombinant parainfluenza virus expression systems and vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant parainfluenza virus expression systems and vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant parainfluenza virus expression systems and vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2813756